COLUMBIA, Md.--(BUSINESS WIRE)--Subsequent to the end of the year, CELSION CORPORATION (NASDAQ: CLN) reported two important milestones in the development of its lead drug ThermoDox®, and in its transformation to a company totally focused on the development and commercialization of oncology drugs. On January 18th, the FDA notified the company that its Special Protocol Assessment (SPA) submission for Phase III liver cancer had been agreed to. On January 15th the FDA provided supportive notification regarding Celsion’s proposal for an open label phase II study for the treatment of patients with recurrent breast cancer at the chest wall.
